1	Title: Risk Factors Associated with Increased Antibiotic Use in COVID-19 Hospitalized Patients
2	
3 4	Authors: Alysa J. Martin, PharmD <sup>1</sup> #; Stephanie Shulder, PharmD, BCIDP <sup>1</sup> ; David Dobrzynski, MD <sup>2</sup> ; Katelyn Quartuccio, PharmD, BCPS <sup>3</sup> ; Kelly E. Pillinger, PharmD, BCPS-AQ ID, BCIDP <sup>1</sup>
5	
6 7	<sup>1</sup> University of Rochester Medical Center Strong Memorial Hospital, Department of Pharmacy, Rochester, NY, USA
8	<sup>2</sup> University of Rochester Medical Center, Division of Infectious Diseases, Rochester, NY, USA
9 10	<sup>3</sup> University of Rochester Medical Center Highland Hospital, Department of Pharmacy, Rochester, NY, USA
11	
12	# Address correspondence to: Alysa J. Martin, PharmD, alysa_martin@urmc.rochester.edu
13	
14	Running title: COVID-19 antibiotic risk factors
15	Key words: COVID-19, antimicrobial stewardship, antibiotics, community-acquired pneumonia,
16	bacterial infection
17	
18	
19	
20	
21	
22	
23	

#### 24 Abstract

25 Literature suggests that antibiotic prescribing in COVID-19 patients is high, despite low 26 rates of confirmed bacterial infection. There are little data on what drives prescribing habits. 27 This retrospective, multi-center, observational study sought to determine antibiotic prescribing rates and risk factors for antibiotic prescribing in hospitalized patients. Patients admitted from 28 29 March 1, 2020 to May 31, 2020 and treated for PCR-confirmed COVID-19 were included. The 30 primary endpoint was the rate of antibiotic use during hospitalization. Secondary endpoints included risk factors associated with antibiotic use, risk factors associated with receiving more 31 32 than one antibiotic course, and rate of microbiologically confirmed infections. A total of 208 33 encounters (198 patients) were included in the final analysis. Eighty-three percent of patients 34 received at least one course of antibiotics, despite low rates of microbiologically confirmed infection (12%). Almost one-third of patients (30%) received more than one course of 35 36 antibiotics. There was a low rate of respiratory cultures obtained (32%). Risk factors identified 37 in a univariate analysis for both antibiotic prescribing and receiving more than one course of antibiotics were more serious illness, increased hospital length of stay, ICU admission, 38 39 mechanical ventilation, and ARDS. This study highlights the need for increased antibiotic stewardship practices in COVID-19 patients. Further studies should be conducted to determine 40 41 the utility of different stewardship initiatives in COVID-19 patients.

42

43

### 45 Introduction

The novel coronavirus disease identified in 2019 (COVID-19) is caused by a betacoronavirus known as SARS-CoV-2. Despite the fact that COVID-19 is a viral infection, clinical manifestations may present similarly to a bacterial pneumonia.<sup>1</sup> Patients often present with respiratory symptoms including fever, cough, dyspnea, and bilateral changes on chest imaging.<sup>1</sup> It can be difficult to determine if patients have a bacterial respiratory coinfection along with COVID-19 infection. This may lead to over-prescribing of antibiotics in patients with COVID-19.

Despite bacterial coinfection being reported in 2-8% of patients, rates of antibiotic 53 prescribing have ranged from 57-95% in hospitalized patients.<sup>1-7</sup> Additionally, there are reports 54 of increased consumption of antibiotics during the COVID-19 pandemic.<sup>6-9</sup> Over-prescribing of 55 56 antibiotics may increase the risk of adverse side effects, nosocomial infection, and antibiotic 57 resistance. Several organizational guidelines recommend starting empiric antibiotic therapy if concern for bacterial pneumonia or sepsis, but to re-evaluate daily and de-escalate or 58 discontinue if no evidence of bacterial infection.<sup>10-14</sup> Furthermore, they emphasize the 59 importance of antimicrobial stewardship programs which may help to avoid starting antibiotics 60 reflexively or continuing unnecessary courses. The World Health Organization (WHO) has 61 released guidance which discourages the use of antibiotic therapy for patients with COVID-19 62 infections unless signs and symptoms of a bacterial infection exist.<sup>11</sup> 63

64 Unfortunately, there are limited data to date describing the need or role for antibiotics
 65 in COVID-19 or outcomes for patients who receive them. Additionally, little is known regarding

66	risk factors associated with antibiotic use. There have only been two previous studies which
67	evaluated prescribing trends, and risk factors of antibiotic prescribing. Both studies focused on
68	prescribing rates, coinfections and risk factors associated with antibiotic prescribing within the
69	first 48 hours of admission. <sup>4,5</sup>
70	The purpose of this study was to evaluate the rate of antibiotic use in COVID-19 patients
71	and risk factors associated with antibiotic use throughout hospitalization. A better
72	understanding of prescribing practices can be used to evaluate opportunities for antibiotic
73	stewardship for future patients with COVID-19.
74	Methods
75	Study design
76	This was a multi-center, retrospective, observational study of antibiotic prescribing
77	trends in patients with confirmed COVID-19 at three hospitals within the University of
78	Rochester Medical Center.
79	Patients 18 years and older admitted from March 1, 2020 to May 31, 2020 and treated
80	for PCR-confirmed COVID-19 were eligible for inclusion. Patients did not meet inclusion criteria
81	if they were only treated in the emergency department without subsequent admission. Patients
82	could be included more than once if they had multiple admissions within the study period.
83	Patients were excluded if they were asymptomatic. Data were collected until June 30, 2020.
84	This study was reviewed and deemed exempt by the Institutional Review Board.
85	Data Collection

86 Patients were identified from the electronic health record based on a positive or 87 presumptive positive SARS-CoV-2 PCR test. Baseline data including age, gender, race, weight, height, comorbidities, date of first positive SARS-CoV-2 PCR, and admission and discharge dates 88 were collected. Labs on admission (or at time of positive test if nosocomial transmission), 89 90 microbiologic data, clinical symptoms, imaging, antibiotic data, COVID-19 investigational or off-91 label treatment, death and re-admission within 30 days were also collected. 92 Outcomes 93 The primary endpoint of the study was the rate of antibiotic use in patients admitted for 94 COVID-19. Secondary endpoints included risk factors associated with antibiotic use, risk factors 95 associated with receiving more than one antibiotic course, and rate of microbiologicallyconfirmed infections. 96 Statistical Analysis 97 Data were analyzed using R statistical software version 4.0.2 (Boston, MA) with a p-98 value < 0.05 considered statistically significant. Continuous variables were described using a 99 100 median with interquartile range (IQR). Categorical variables were analyzed using Fisher's exact 101 testing. Two-sample Wilcoxon test was used for continuous variables. To evaluate risk factors 102 associated with antibiotic use, a univariate analysis was conducted and variables with a p-value 103 ≤ 0.05 were included in a multivariate logistic regression. In addition, a univariate analysis and multivariate logistic regression were conducted for patients receiving more than one course of 104 105 antibiotics with the following pre-specified variables included if P < 0.05 and clinically 106 significant: length of stay, intensive care unit (ICU) admission, ICU length of stay, mechanical

107 ventilation, more than one COVID-19 related admission, microbiologically-confirmed infection,

108 time from SARS-CoV-2 collection date to initial antibiotic start, and 28-day mortality.

109

110 Results:

A total of 228 encounters met inclusion criteria, with twenty excluded due to 111 112 asymptomatic disease, leaving 208 encounters included in the final analysis (n=198 patients). 113 The median age was 69 years (IQR 60-80) and 50% (105/208) were male (Table 1). The most common comorbidities were hypertension (143/208, 69%), obesity (81/208, 39%), and diabetes 114 115 (81/208, 39%). Of 208 encounters, 83% of patients received at least one course of antibiotics. 116 Antibiotic prescribing did not differ based on gender, age, race, or comorbidities. Even though a 117 small subset of patients (n=11), all immunocompromised patients received antibiotics (Table 1). 118 While rates of antibiotic prescribing overall were high, we saw a temporal decrease in antibiotic prescribing. When consolidating encounters by month of admission, rates of 119 120 antibiotic prescribing were highest in March, with 88% (42/49) of encounters receiving 121 antibiotics, compared to 82% (127/155) in April and 75% (3/4) in May. Rates of antibiotic prescribing were significantly higher in patients admitted to the ICU, 122 requiring O2 support (including ventimask, BiPAP and mechanical ventilation), and with acute 123 124 respiratory distress syndrome (ARDS) (p < 0.0001). Median length of stay was 6.5 days longer in those receiving antibiotics (p < 0.0001). Patients who received investigational or off-label 125 therapy for COVID-19 were also more often prescribed antibiotics (p = 0.0328). Of patients who 126 127 died within 28 days, 92% received antibiotics (47/51, p=0.017). Additionally, median aspartate

transaminase (AST), lactate dehydrogenase (LDH), and procalcitonin (PCT) at baseline were
higher in those who were prescribed antibiotics (Table 1). PCT > 0.5 was associated with a
higher rate of antibiotic prescribing [94% (44/47) prescribed antibiotics vs. 6% (3/47) did not
receive antibiotics, OR 3.76, Cl 1.09-20.1, p = 0.03]. Of patients with a PCT > 0.5, 43/47 had
respiratory or blood cultures obtained. Microbiologically confirmed bacterial infection was
present in 12% (5/43).

Respiratory cultures were obtained in 32% (67/208) of patients. In total, 19% (13/67) 134 135 were positive (Table 2). Staphylococcus aureus was identified in 5 (38%) of 13 positive 136 respiratory culture results (3% of total patients). Blood cultures were obtained in the majority 137 of patients (149/208, 72%), but few were positive (12/149, 7%). All influenza PCR and Legionella 138 urinary antigen (UAg) tests were negative. Two Streptococcus pneumoniae UAg tests were 139 positive (2.4%, 2/84). In addition, 75 patients (36%) were screened for MRSA nares 140 colonization. Overall, there were 24 microbiologically-confirmed infections treated with antibiotics [11% (24/208) overall]. In a subgroup analysis, patients with microbiologically 141 142 confirmed infections were more likely to receive more than one course of antibiotics, be 143 admitted to the ICU, and have a longer length of stay.

The most frequently prescribed initial antibiotics were ceftriaxone in 113 (66%) patients and azithromycin in 99 (57%) patients for community acquired pneumonia (CAP), followed by an anti-pseudomonal beta lactam (23%) and vancomycin (23%) for hospital acquired pneumonia (HAP) or ventilator associated (VAP) (Figures 1 and 2). The median time from SARS-CoV-2 collection to antibiotic initiation was one day (IQR 1-4.5 days). Median duration of therapy for the initial course of antibiotics was five days (IQR 2-6 days). In 41 (24%) patients, the initial regimen was changed; 17 patients were escalated to broader therapy (42%) and 15
patients were de-escalated to narrower therapy (37%). Nine (22%) had another regimen change
such as intravenous to oral conversion or changed to another agent with similar spectrum of
activity.

154 Fifty-two patients (30%) received a second course of antibiotics and 19 patients (11%) 155 received more than 2 antibiotic courses during hospitalization. The most frequently prescribed 156 antibiotics included an anti-pseudomonal beta lactam (58%) and vancomycin (58%) for 157 HAP/VAP (Figures 1 and 2). The median duration of second course antibiotics was 6 days (IQR 3-158 8.25). Duration of admission, ICU admission, ICU LOS, mechanical ventilation, microbiologically 159 confirmed infection, and duration of initial course of antibiotics were all risk factors for 160 receiving more than one course of antibiotics (Table 3). Based on the number of patients 161 receiving more than one course of antibiotics, and of the variables that were both statistically 162 significant and clinically relevant on univariate analysis, we chose to include ICU admission, 163 mechanical ventilation, microbiologically confirmed infection, duration of admission and ICU LOS in our multivariate analysis. ICU length of stay was the only variable found to be a 164 statistically significant in the multivariate analysis. (Table 4). 165

166 Discussion

167 In this multi-center study of patients hospitalized with COVID-19, we found an overall 168 high rate of antibiotic prescribing, with 83% of patients receiving antibiotics. Of these patients, 169 30% received at least one additional course of antibiotics during hospitalization, increasing the 170 overall antibiotic exposure. Despite the high rate of antibiotic prescribing, there were low rates

of bacterial coinfection, with only 12% of patients having microbiologically confirmed infection. 171 172 These findings are similar to the results of previous studies, suggesting the need for strategies to help clinicians judiciously prescribe antibiotics in patients with COVID-19.<sup>1-5,15</sup> Interestingly. 173 while still low, our rate of bacterial coinfection was higher compared to other US studies. 174 175 Compared to these previous studies, we had higher rates of ICU admission and mechanically ventilated patients.<sup>4,5</sup> In our study, we reported microbiologic data throughout hospitalization, 176 177 and even during multiple admissions whereas these two previous studies only reported the first 178 48 hours. This likely contributed to higher rates of microbiologically confirmed infections in our 179 study. Patients with microbiologically confirmed infections were more likely to receive more 180 than one course of antibiotics, be admitted to the ICU, and have a longer length of stay. While 181 this may suggest patients with bacterial coinfection are more likely to have serious illness, the 182 higher rate of microbiologically confirmed infections may also be explained by bacterial 183 infections acquired during hospitalization. Additional courses of antibiotics were often 184 prescribed for empiric or targeted treatment of nosocomial infection. Early in the pandemic, little was known regarding COVID-19 presentation and disease 185 progression. Additionally, there was a paucity of data suggesting bacterial co-infection was low 186 in the beginning of the COVID-19 pandemic. Thus, guideline recommendations were evolving 187 188 throughout the study period. Initial recommendations often encouraged antibiotic use. Within 189 the University of Rochester Medical Center, our practices and institutional guidelines recommended initiating empiric antibiotics in the majority of COVID-19 patients. As information 190 191 became more available, and recommendations changed, our antibiotic prescribing decreased.

This was reflected in the temporal decline in antibiotic prescribing we observed from March toMay.

194 There were several indicators that serious illness increased the risk of antibiotic 195 prescribing. Initial antibiotic prescribing was more likely in patients with certain elevated laboratory values (PCT, AST, and LDH), longer length of stay, ICU admission, longer ICU length of 196 197 stay, and administration of off-label or investigational therapy for COVID-19. Additionally, all patients with ARDS or requiring more invasive O2 support received at least 1 course of 198 199 antibiotics. These findings are consistent with previous studies which found patients were more likely to receive antibiotics if they had severe disease upon presentation.<sup>4,5</sup> To our knowledge, 200 201 this is the first study to report rates of additional antibiotic prescribing beyond initial empiric 202 therapy. Patients with COVID-19 often have a prolonged hospitalization due to the underlying 203 disease process. Our median LOS was significantly longer in patients which received at least one 204 antibiotic course (p < 0.001), and prolonged hospitalization may also increase the potential for additional antibiotic exposure. Thus, it is important to understand antibiotic prescribing trends 205 and associated risk factors beyond the first course. Our study found that nearly one-third of all 206 207 patients received two or more courses of antibiotics. Variables associated with receiving two or more antibiotic courses included: longer length of stay, ICU admission, longer ICU length of 208 209 stay, and mechanical ventilation. This is likely explained as these are all risk factors for hospital-210 acquired illness and antibiotics were commonly prescribed for nosocomial infection (e.g. HAP/VAP). 211

Procalcitonin has been suggested as a potentially useful biomarker to differentiate
bacterial and viral infections and assist with clinical decision-making. A Cochrane review of

acute respiratory infections concluded that use of procalcitonin to guide treatment decisions 214 215 results in lower antibiotic consumption, lower mortality, and fewer antibiotic-related side effects.<sup>16</sup> In contrast, a recent study in pneumonia comparing procalcitonin-guided treatment 216 217 and usual care found no difference in duration of antibiotic treatment or antibiotic-associated outcomes.<sup>17</sup> The ATS/IDSA CAP guidelines strongly advise initiating antibiotics based off clinical 218 judgement rather than procalcitonin alone.<sup>13</sup> In COVID-19 patients specifically, a recent 219 220 retrospective cohort study found that patients with COVID-19 consistently had negative procalcitonin levels (< 0.25 ng/mL).<sup>18</sup> Conversely, elevated procalcitonin levels have been 221 associated with severity of illness or mortality.<sup>19</sup> Elevated procalcitonin may represent bacterial 222 coinfection, but could also be due to immune dysregulation.<sup>20</sup> At our sites, the patients 223 prescribed antibiotics had significantly higher baseline procalcitonin, however the median was 224 225 only 0.28. In a subgroup analysis focusing on patients who had a procalcitonin of > 0.5, 94% of patients received antibiotics. It is unclear at this time the utility of using procalcitonin to 226 determine if there is bacterial co-infection with COVID-19. 227

Previous studies have shown high rates of broad-spectrum antibiotics for initial empiric 228 therapy in COVID-19 patients.<sup>1,3-6,8,15</sup> However, in our patient population, most patients were 229 treated initially for CAP. The most common agents included ceftriaxone plus azithromycin, 230 which is consistent with the 2019 ATS/IDSA recommendations for CAP.<sup>13</sup> During the initial 231 232 antibiotic course, 36.6% of patients were de-escalated to narrower therapy. Not surprisingly, patients that received a second course of antibiotics were more likely to receive broad-233 spectrum antimicrobials; over half of patients who received more than one course of antibiotics 234 235 were treated for HAP/VAP and prescribed an anti-pseudomonal beta lactam (i.e cefepime or

piperacillin/tazobactam.) Respiratory cultures were obtained in only 30.2% of patients, with a 236 237 large number of patients receiving empiric treatment for CAP, HAP or VAP. In part, the low number of respiratory cultures obtained may be due to the symptomatology of disease, with 238 the majority of patients experiencing dry, non-productive cough.<sup>1</sup> Additionally, early in the 239 240 pandemic, there were concerns regarding transmission and aerosolization, which added additional challenges to obtaining respiratory cultures. In addition, the 2019 ATS/IDSA CAP 241 242 guidelines do not recommend routine sputum gram stain and culture in patients with non-243 severe CAP or those without multi-drug resistant organism risk factors due to overall poor yield and detection of organisms.<sup>13</sup> However, respiratory cultures are recommended in patients 244 being treated empirically for MDR organisms, and in those being treated for HAP/VAP.<sup>13,14</sup> 245 246 Respiratory cultures were not obtained in all patients who met these criteria. Obtaining 247 respiratory cultures and other microbiologic data, when possible, on patients treated with 248 broad spectrum antibiotics can potentially help with de-escalation of therapy. One limitation of this study is its retrospective design. Laboratory and microbiologic 249 250 data collected were not consistent amongst all patients. We found duration of admission and 251 ICU length of stay to be associated with higher antibiotic use, however it is difficult to say that 252 these are true risk factors for antibiotic prescribing. Instead, this difference was likely due to 253 antibiotic prescribing being higher in patients with more serious illness, and perhaps longer 254 admission leading to increased risk of nosocomial infections and subsequent antibiotic courses.

Additionally, we did not perform a time adjusted analysis. Another limitation is that the vast majority of patients within our study received antibiotics which could have affected our ability

230 majority of patients within our study received antibiotics when could have anected our ability

257 to detect differences between the two groups.

258	While there were limitations of this study, there were also several strengths. This study
259	was multi-site, including three hospitals within the University of Rochester Medical Center: two
260	community hospitals and a tertiary academic medical center. Therefore, the results of this
261	study may be generalizable to similar sites. Finally, as previously mentioned, this is the first
262	study to assess overall antibiotic use throughout hospitalization, and determine risk factors for
263	additional antibiotic courses. Many patients with COVID-19 have prolonged hospitalization,
264	increasing the risk for antibiotic exposure. Our study examined antibiotic use that is more
265	representative of hospitalized COVID-19 patients.
266	Conclusions
267	Our study found high rates of antibiotic prescribing, despite low rates of respiratory
268	cultures and confirmed microbiologic infections. Antibiotic prescribing was higher in patients

with elevated PCT, longer LOS, ICU admission, 28-day mortality, investigational or off-label

treatment for COVID-19, ARDS, and invasive O2 support. Nearly one-third of patients were

treated with more than one antibiotic course during hospitalization. Patients who received two

or more antibiotic courses were more likely to have longer ICU LOS as demonstrated by the

- 273 multivariate analysis. These data highlight a role for antimicrobial stewardship during the
- 274 COVID-19 pandemic. Further studies are needed to examine the impact of antimicrobial

stewardship initiatives in patients with COVID-19 and assess if antibiotic prescribing practices
have changed with increasing information related to bacterial co-infection that wasn't available

at the beginning of the pandemic.

### 279 Acknowledgements

- 280 The authors thank Raquel Roberts, PharmD for her assistance with data collection. There was
- 281 no funding for the study. The authors report no conflict of interest.

## 282 Tables and Figures


<b>Baseline Characteristic</b>	Total	Antibiotics	No Antibiotics	P-value
		n=172	n=36	
Male gender	105 (50.5)	84 (48.8)	21 (55.6)	0.43
Age, years (median, IQR)	69.0 (60-80)	70.0 (61-81)	65.5 (47-77)	0.12
Race				0.56
Caucasian	116 (55.7)	98 (56.9)	18 (47.2)	
Black/African American	69 (33.2)	53 (30.8)	16 (44.4)	
Asian	2 (1.0)	2 (1.2)	0 (0)	
Other	6 (2.9)	6 (3.5)	0 (0)	
Unknown	15 (7.2)	13 (7.6)	2 (5.6)	
Comorbidities				
Hypertension	143 (68.8)	116 (67.4)	27 (72.2)	0.43
Diabetes	81 (38.9)	70 (23.2)	11 (27.8)	0.35
Obesity	80 (38.5)	66 (38.4)	14 (38.9)	>0.99
Cardiac Disease	56 (26.9)	50 (29.1)	6 (16.7)	0.15
Chronic Lung Disease	43 (20.7)	37 (21.5)	6 (16.7)	0.65
СКD	45 (21.7)	40 (23.2)	5 (13.9)	0.20
None	21 (10.1)	17 (9.9)	4 (11.1)	0.77
Immunocompromised <sup>a</sup>	11 (5.3)	11 (6.4)	0 (0)	0.22
Labs (median, IQR)				
AST, U/L	43 (31-65)	46 (33.25-65)	35 (26.75-49)	0.02
ALT, U/L	30 (20-46)	29.5 (20-45)	32.5 (20-49.5)	0.83
Scr, mg/dL	1.130 (0.84-	1.14 (0.84-	1.06 (0.81-1.3)	0.14
	1.64)	1.725)		
WBC	7.30 (5.50-	7.4 (5.5-10.7)	6.8 (4.8-9.2)	0.11
	10.50)			
ALC	1.0 (0.7-1.3)	1.0 (0.7-1.3)	1.1 (0.5-1.4)	0.10
CRP	93.0 (39.5-	93 (39.5-	73 (37.5-118.5)	0.37
	134.5)	134.5)		
LDH	344 (264.5-	348 (285-	294 (239-387)	0.03
	467)	474)		
Ferritin	627 (304-1086)	627 (309-	589 (235-980)	0.45
		1133.5)		


D-dimer	1.26 (0.63-	1.37 (0.71-	0.86 (0.6-1.6)	0.24
D-umer	2.08)	2.1)	0.80 (0.0-1.0)	0.24
РСТ	0.215 (0.120-	0.28 (0.13-	0.13 (0.09-	<0.01
	0.620)	0.63)	0.20)	<0.01
Symptoms Prior to Admission	0.0207	0.037	0.201	
Fever	120 (57.7)	101 (58.7)	19 (52.8)	0.59
Respiratory Symptoms	180 (86.5)	152 (88.4)	28 (75)	0.10
Gastrointestinal symptoms	76 (36.5)	60 (34.9)	16 (41.7)	0.34
Anosmia/Hyperosmia/Hypogeusia	11 (5.3)	10 (5.8)	1 (2.8)	0.69
Symptom duration prior to	6.0 (3-9)	6.0 (3-9)	7.5 (4.75-9)	0.16
admission, days (median, IQR)	0.0 (3 5)	0.0 (3 3)	7.5 (4.75 5)	0.10
Location prior to admit				0.08
Home	140 (67.3)	110 (63.9)	30 (80.5)	
SNF	60 (28.8)	54 (31.4)	6 (16.7)	
Transfer from OSH	8 (3.8)	8 (4.7)	0 (0)	
Duration of admission, days	11 (5-22)	12 (5.75-25)	5.5 (4-11.3)	<0.01
(median, IQR)		(===================================		
ICU admission	104	102 (58.9)	2 (5.6)	<0.01
ICU LOS, days (median, IQR)	10 (3-18)	10 (3.25-18)	6.5 (6.25-6.75)	0.59
O2 support				<0.01
Room Air	40 (19.2)	24 (13.9)	16 (44.4)	
Standard Nasal Cannula	67 (32.2)	49 (28.5)	18 (50.0)	
HFNC/Venti Mask	19 (9.1)	17 (9.9)	2 (5.6)	
BiPAP	5 (2.4)	5 (2.9)	0 (0)	
Non-rebreather	7 (3.4)	7 (4.1)	0 (0)	
Mechanical ventilation	70 (33.7)	70 (40.7)	0 (0)	
ARDS	78 (37.5)	78 (45.3)	0 (0)	<0.01
Received investigational or off-label	37 (17.8)	35 (20.2)	2 (5.6)	0.03
transfer for COVID-19				
28-day mortality	51 (24.5)	48 (27.9)	3 (8.3)	0.02
30-day readmission	16 (7.7)	12 (6.9)	4 (11.1)	0.75
More than 1 admission for COVID-19	12 (5.8)	8 (4.7)	4 (11.1)	0.23
Time from discharge to COVID-19	7 (4.5-12.25)	5 (2.75-11.5)	10 (7.75-12.5)	0.22
readmission, days (median, IQR)	if: a d			

readmission, days (median, IQR) ()= Percentages unless otherwise specified a = immunocompromised patients were defined as those with previous solid organ transplant, active cancer receiving chemotherapy, patients on biologic therapy, and uncontrolled HIV IOR = Interguartile Range CKD = chronic kidney disease AST = Aspartate aminotransferase ALT = Alanine aminotransferase SCr= Serum Creatinine WBC = White blood cell count ALC = Absolute lymphocyte count CRP = C-reactive protein LDH= Lactate dehydrogenase PCT = procalcitonin SNF = Skilled nursing facility HFNC = high flow nasal cannula Respiratory symptoms were defined as hypoxia, SOB, cough

Table 2: Microbiologic	Data		
Micro Data	Antibiotics n=172	No antibiotics n=36	P-value
Microbiologically- confirmed infection	24 (14.0)	0 (0)	0.02
Respiratory cultures obtained	66 (38.3)	1 (2.7)	<0.01
No growth	53 [80.3]	1 [100]	>0.99
Positive	13 [19.7]	0 [0]	>0.99
Blood cx obtained	135 (78.5)	14 (38.9)	<0.01
No growth	123 [91.1]	14 [100]	0.61
Positive	12 [8.9]	0 [0]	0.61
Influenza PCR obtained	75 (43.6)	13 (36.1)	0.46
Strep pneumoniae urinary antigen obtained	82 (47.7)	6 (16.7)	<0.01
Positive	2 [2.4]	0 [0]	>0.99
Negative	80 [97.6]	6 [100]	>0.99
Legionella urinary antigen obtained	87 (50.5)	6 (16.7)	<0.01
MRSA nares obtained	73 (42.4)	2 (5.6)	<0.01
Positive	4 [5.5]	0 [0]	>0.99
Negative	69 [94.5]	2 [100]	>0.99

()= percent unless otherwise specified





	Univariate Analysis			Multivariate analysis		
Variable	1 antibiotic course n= 120 (%)	> 1 antibiotic course n=52 (%)	P value	Odds ratio	95% CI	P-value
Length of stay, days (median, IQR)	8 (4-15)	25 (18.75-37)	<0.01	1.01	0.99-1.04	0.32
ICU admission	51 (42.5)	49 (94.2)	< 0.01	1.96	0.38-11.10	0.42
ICU length of stay, days (median, IQR)	5 (3-9)	18 (12-26)	<0.01	1.14	1.06-1.26	<0.01
Mechanical ventilation	25 (20.8)	45 (86.5)	<0.01	1.83	0.46-7.61	0.39
More than 1 COVID-19 related admission	7 (5.8)	1 (1.9)	0.44			
Microbiologically- confirmed infection	4 (3.3)	20 (38.5)	<0.01	3.31	0.86-15.26	0.10
Duration of initial course of antibiotics, days (median, IQR)	4 (2-5.25)	5 (4-7)	<0.01			
Time from SARS- CoV-2 collect date	1 (0-5)	2 (0-2)	0.51			

	to initial antibiotic start, days (median, IQR)					
308	28-day mortality ()= Percentages unle	33 (27.5) ss otherwise sn	14 (38.9) ecified	>0.99		
309	()- i cicentages une	.35 Other wise sp	eenieu			
310						
311						
312						
313						
314						
315						
316						
317						
318						
319						
320						
321						
322 323						
323						
325						
326						
327						
328						
329						
330						
331						
332						
552						

### 333 References:

334 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with 1. 335 COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England) 2020;395:1054-62. 336 Crotty MP, Dominguez EA, Akins R, et al. Investigation of subsequent and co-infections 2. 337 associated with SARS-CoV-2 (COVID-19) in hospitalized patients. medRxiv 2020. 338 3. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co-infection in individuals with 339 coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clinical infectious diseases : 340 an official publication of the Infectious Diseases Society of America 2020. 341 4. Vaughn VM, Gandhi T, Petty LA, et al. Empiric Antibacterial Therapy and Community-onset 342 Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study. 2020. 343 5. Wei W, Ortwine JK, Mang NS, Joseph C, Hall BC, Prokesch BC. Limited Role for Antibiotics in 344 COVID-19: Scarce Evidence of Bacterial Coinfection. Available at SSRN 3622388 2020. 345 6. Beović B, Doušak M, Ferreira-Coimbra J, et al. Antibiotic use in patients with COVID-19: a 346 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey. Journal of Antimicrobial 347 Chemotherapy 2020. 348 Buehrle DJ, Decker BK, Wagener MM, et al. Antibiotic consumption and stewardship at a 7. 349 hospital outside of an early Coronavirus disease 2019 epicentre. 2020:AAC.01011-20. 350 8. Abelenda-Alonso G, Padullés A, Rombauts A, et al. Antibiotic prescription during the COVID-19 351 pandemic: A biphasic pattern. Infection Control & Hospital Epidemiology 2020:1-2. 352 9. Nestler M, Godbout E, Lee K, et al. Impact of COVID-19 on Pneumonia-Focused Antibiotic Use at 353 an Academic Medical Center. Infection control and hospital epidemiology 2020:1-9. 354 COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment 10. 355 Guidelines. National Institutes of Health 356 357 11. Clinical management of COVID-19 Interim Guidance - May 2020. World Health Organization. 358 2020, at https://www.who.int/publications-detail/clinical-management-of-covid-19.) 359 Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the 12. 360 management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive care medicine 361 2020;46:854-87. 362 13. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-363 acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and 364 Infectious Diseases Society of America. 2019;200:e45-e67. 365 14. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and 366 Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of 367 America and the American Thoracic Society. Clinical Infectious Diseases 2016;63:e61-e111. 368 15. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic 369 review and meta-analysis. The Journal of infection 2020;81:266-75. 370 Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute 16. 371 respiratory tract infections. The Cochrane database of systematic reviews 2017;10:Cd007498. 372 Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-Guided Use of Antibiotics for Lower 17. 373 Respiratory Tract Infection. 2018;379:236-49. 374 18. Bass J, Singh A, Williams R, Lindner DH. Procalcitonin and COVID-19: A Reliable Clinical Tool. 375 2020. 376 19. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. International journal 377 of antimicrobial agents 2020;56:106051. 378 20. Shah V. Advances in Motion 2020.

- 379
  380
  381
  382

# Tables and Figures

Baseline Characteristic	Total	Antibiotics	No Antibiotics	P-value
		n=172	n=36	
Male gender	105 (50.5)	84 (48.8)	21 (55.6)	0.43
Age, years (median, IQR)	69.0 (60-80)	70.0 (61-81)	65.5 (47-77)	0.12
Race				0.56
Caucasian	116 (55.7)	98 (56.9)	18 (47.2)	
Black/African American	69 (33.2)	53 (30.8)	16 (44.4)	
Asian	2 (1.0)	2 (1.2)	0 (0)	
Other	6 (2.9)	6 (3.5)	0 (0)	
Unknown	15 (7.2)	13 (7.6)	2 (5.6)	
Comorbidities				
Hypertension	143 (68.8)	116 (67.4)	27 (72.2)	0.43
Diabetes	81 (38.9)	70 (23.2)	11 (27.8)	0.35
Obesity	80 (38.5)	66 (38.4)	14 (38.9)	>0.99
Cardiac Disease	56 (26.9)	50 (29.1)	6 (16.7)	0.15
Chronic Lung Disease	43 (20.7)	37 (21.5)	6 (16.7)	0.65
СКД	45 (21.7)	40 (23.2)	5 (13.9)	0.20
None	21 (10.1)	17 (9.9)	4 (11.1)	0.77
Immunocompromised <sup>a</sup>	11 (5.3)	11 (6.4)	0 (0)	0.22
Labs (median, IQR)				
AST, U/L	43 (31-65)	46 (33.25-65)	35 (26.75-49)	0.02
ALT, U/L	30 (20-46)	29.5 (20-45)	32.5 (20-49.5)	0.83
Scr, mg/dL	1.130 (0.84-	1.14 (0.84-	1.06 (0.81-1.3)	0.14
	1.64)	1.725)		
WBC	7.30 (5.50-	7.4 (5.5-10.7)	6.8 (4.8-9.2)	0.11
	10.50)			
ALC	1.0 (0.7-1.3)	1.0 (0.7-1.3)	1.1 (0.5-1.4)	0.10
CRP	93.0 (39.5-	93 (39.5-	73 (37.5-118.5)	0.37
	134.5)	134.5)		
LDH	344 (264.5-	348 (285-	294 (239-387)	0.03
	467)	474)		
Ferritin	627 (304-1086)	627 (309-	589 (235-980)	0.45
		1133.5)		
D-dimer	1.26 (0.63-	1.37 (0.71-	0.86 (0.6-1.6)	0.24
	2.08)	2.1)		
РСТ	0.215 (0.120-	0.28 (0.13-	0.13 (0.09-	<0.01
	0.620)	0.63)	0.20)	
Symptoms Prior to Admission				
Fever	120 (57.7)	101 (58.7)	19 (52.8)	0.59
Respiratory Symptoms	180 (86.5)	152 (88.4)	28 (75)	0.10


	1	1	1	
Gastrointestinal symptoms	76 (36.5)	60 (34.9)	16 (41.7)	0.34
Anosmia/Hyperosmia/Hypogeusia	11 (5.3)	10 (5.8)	1 (2.8)	0.69
Symptom duration prior to	6.0 (3-9)	6.0 (3-9)	7.5 (4.75-9)	0.16
admission, days (median, IQR)				
Location prior to admit				0.08
Home	140 (67.3)	110 (63.9)	30 (80.5)	
SNF	60 (28.8)	54 (31.4)	6 (16.7)	
Transfer from OSH	8 (3.8)	8 (4.7)	0 (0)	
Duration of admission, days	11 (5-22)	12 (5.75-25)	5.5 (4-11.3)	<0.01
(median, IQR)				
ICU admission	104	102 (58.9)	2 (5.6)	<0.01
ICU LOS, days (median, IQR)	10 (3-18)	10 (3.25-18)	6.5 (6.25-6.75)	0.59
O2 support				<0.01
Room Air	40 (19.2)	24 (13.9)	16 (44.4)	
Standard Nasal Cannula	67 (32.2)	49 (28.5)	18 (50.0)	
HFNC/Venti Mask	19 (9.1)	17 (9.9)	2 (5.6)	
BiPAP	5 (2.4)	5 (2.9)	0 (0)	
Non-rebreather	7 (3.4)	7 (4.1)	0 (0)	
Mechanical ventilation	70 (33.7)	70 (40.7)	0 (0)	
ARDS	78 (37.5)	78 (45.3)	0 (0)	<0.01
Received investigational or off-label	37 (17.8)	35 (20.2)	2 (5.6)	0.03
transfer for COVID-19				
28-day mortality	51 (24.5)	48 (27.9)	3 (8.3)	0.02
30-day readmission	16 (7.7)	12 (6.9)	4 (11.1)	0.75
More than 1 admission for COVID-19	12 (5.8)	8 (4.7)	4 (11.1)	0.23
Time from discharge to COVID-19	7 (4.5-12.25)	5 (2.75-11.5)	10 (7.75-12.5)	0.22
readmission, days (median, IQR)				


readmission, days (median, IQR) ()= Percentages unless otherwise specified a = immunocompromised patients were defined as those with previous solid organ transplant, active cancer receiving chemotherapy, patients on biologic therapy, and uncontrolled HIV IOR = Interquartile Range CKD = chronic kidney disease AST = Aspartate aminotransferase ALT = Alanine aminotransferase SCr= Serum Creatinine WBC = White blood cell count ALC = Absolute lymphocyte count CRP = C-reactive protein LDH= Lactate dehydrogenase PCT = procalcitonin SNF = Skilled nursing facility HFNC = high flow nasal cannula RespiratorY symptoms were defined as hypoxia, SOB, cough GI symptoms were defined as nausea, vomiting, diarrhea

Table 2: Microbiologic Micro Data	Antibiotics	No antibiotics	P-value
WICTO Data	n=172	n=36	P-value
Microbiologically- confirmed infection	24 (14.0)	0 (0)	0.02
Respiratory cultures obtained	66 (38.3)	1 (2.7)	<0.01
No growth	53 [80.3]	1 [100]	>0.99
Positive	13 [19.7]	0 [0]	>0.99
Blood cx obtained	135 (78.5)	14 (38.9)	<0.01
No growth	123 [91.1]	14 [100]	0.61
Positive	12 [8.9]	0 [0]	0.61
Influenza PCR obtained	75 (43.6)	13 (36.1)	0.46
Strep pneumoniae urinary antigen obtained	82 (47.7)	6 (16.7)	<0.01
Positive	2 [2.4]	0 [0]	>0.99
Negative	80 [97.6]	6 [100]	>0.99
Legionella urinary antigen obtained	87 (50.5)	6 (16.7)	<0.01
MRSA nares obtained	73 (42.4)	2 (5.6)	< 0.01
Positive	4 [5.5]	0 [0]	>0.99
Negative	69 [94.5]	2 [100]	>0.99

()= percent unless otherwise specified

[]= percent of subset





	Univariate Analysis			Multivar	iate analysis	
Variable	1 antibiotic course n= 120 (%)	> 1 antibiotic course n=52 (%)	P value	Odds ratio	95% CI	P-value
Length of stay, days (median, IQR)	8 (4-15)	25 (18.75-37)	<0.01	1.01	0.99-1.04	0.32
ICU admission	51 (42.5)	49 (94.2)	<0.01	1.96	0.38-11.10	0.42
ICU length of stay, days (median, IQR)	5 (3-9)	18 (12-26)	<0.01	1.14	1.06-1.26	<0.01
Mechanical ventilation	25 (20.8)	45 (86.5)	<0.01	1.83	0.46-7.61	0.39
More than 1 COVID-19 related admission	7 (5.8)	1 (1.9)	0.44			
Microbiologically- confirmed infection	4 (3.3)	20 (38.5)	<0.01	3.31	0.86-15.26	0.10
Duration of initial course of antibiotics, days (median, IQR)	4 (2-5.25)	5 (4-7)	<0.01			
Time from SARS- CoV-2 collect date to initial antibiotic start, days (median, IQR)	1 (0-5)	2 (0-2)	0.51			
28-day mortality	33 (27.5)	14 (38.9)	>0.99			

()= Percentages unless otherwise specified